On December 13, according to Gelonghui, Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that, as the non-public issuance of Stocks fundraising project "Ruibo (Hangzhou) Pharmaceutical Technology Co., Ltd. Research and Development Center Project" has reached the intended operational state for the year 2020, the company intends to conclude the aforementioned fundraising project and use the remaining raised funds of 48.7058 million yuan (including interest) to permanently supplement working capital, with the specific amount for permanent supplementation based on the actual balance of the raised funds special account at the time of transfer.